派罗欣联合利巴韦林治疗慢性丙型肝炎的早期不良反应观察及处理被引量：5

在线阅读下载PDF

导出

摘要目的观察派罗欣(聚乙二醇干扰素α-2a)联合利巴韦林治疗的慢性丙型肝炎患者的早期不良反应。方法回顾性分析了58例应用派罗欣联合利巴韦林治疗的慢性丙型肝炎患者治疗4周的临床资料。结果派罗欣联合利巴韦林治疗的早期不良反应有发热40例(69%),头痛及肌肉关节酸痛36例(62%),胃肠道反应10例(17%),白细胞(WBC)减少44例(76%),血小板(PLT)减少10例(17%),血红蛋白(HGB)下降31例(53%),4例患者因中性细胞数降低而将派罗欣减量,6例患者因胃肠道反应或HGB明显下降将利巴韦林减量。结论派罗欣联合利巴韦林治疗慢性丙型肝炎早期最常见的不良反应是类流感样症状、胃肠道反应、白细胞、中性粒细胞、血小板减少及血红蛋白下降,中性粒细胞减少、胃肠道反应及血红蛋白下降可以导致干扰素及利巴韦林减量,从而影响丙型肝炎的抗病毒疗效。

作者付贤云张立新涂立锐

机构地区济南市传染病医院

出处《中国卫生产业》 2012年第18期67-68,共2页 China Health Industry

关键词派罗欣利巴韦林慢性丙型肝炎不良反应处理

分类号 R512.63 [医药卫生—内科学]

引文网络
相关文献

参考文献6

1National Institutes of Health consensus Development conference Panel Statement: management of hepatitis C[J]. Hepatology,1997, 26:2S-10S.
2病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62. 被引量：1832
3Ghany MG,Strader DB,Thomas DL,et al. Diagnosis,magement,and treat- ment of hepatitis c :all update[J].Hepatology,2009,49(4): 1335-1374.
4徐道振,谢尧,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎疗效、安全性的评估[J].中华传染病杂志,2004,22(4):221-224. 被引量：37
5NIKROO HASHEMI,SIMONA ROSSI,VICTOR J NAVARRO,et al. Safety of peginterferon in the treatment of chronic hepatitis c[J].Expert Opin.Drug Saf, 2008,7(6) : 771-781.
6姜雪强.邹小静.田德英.聚乙二醇干扰素d-2a联合利巴韦林治疗慢性丙型肝炎的疗效及不良反应[J].中西医肝病结合杂志,2010,20(6):335-337.

二级参考文献8

1Sharara AI.Diagnosis and management of chronic hepatitis C[].J Med Liban.1999
2Zeuzem S,Welsch C,Herrmann E.Pharmacokinetics of peginter-ferons[].Seminars in Liver Disease.2003
3Ferenci P.Peginterferon alfa-2a ( 40-kDa) ( Pegasys) for the treatment of patients with chronic hepatitis C[].International Journal of Clinical Practice.2003
4Hadziyannis SJ,Papatheodoridis GV.Peginterferon-alpha2a (40 kDa) for chronic hepatitis C[].Expert Opinion on Pharmacotherapy.2003
5Brouwer JT,Hansen BE,Niesters HG,et al.Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT[].Journal of Hepatology.1999
6Vrolijk JM,Kwekkeboom J,Janssen HL,et al.Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection[].The Journal of Infectious Diseases.2003
7Orito E.HCV genotype as a predictor of response to interferon therapy in patients with chronic hepatitis C[].Japanese Journal of Clinical Medicine.2001
8Fried MW,Shiffman M,Sterling RK,et al.A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype[].The American journal of Gastroenterology.2000